Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
914 articles by Jacob Bell
-
Gilead, Amgen, J&J most likely to buy Otezla, Wall Street predicts
July 18, 2019 -
Kite building out manufacturing as next cell therapy inches to market
July 16, 2019 -
GSK poses challenge to rival AstraZeneca with positive PARP data
July 15, 2019 -
ICER unconvinced peanut allergy drugs are better than just avoiding the food
July 11, 2019 -
New GSK data raises threat to Gilead's star HIV drug
July 10, 2019 -
UK testing Netflix-style payments to boost antibiotics development
July 9, 2019 -
BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals
July 8, 2019 -
BioPharma Dive's 10 biggest stories of the spring
July 3, 2019 -
Once 'bodies for hire,' CROs are finding a new role as data specialists
June 28, 2019 -
Digital is bringing the change clinical trials need, DIA head says
June 28, 2019 -
Aiming for price transparency, Civica Rx hits snag with bundled payments
June 27, 2019 -
FDA officials see 'missed opportunity' with patient outcomes in clinical trials
June 26, 2019 -
Conatus hits all-time low as company explores strategic alternatives
June 25, 2019 -
Merck is on top. Investors worry there's only one way to go.
June 21, 2019 -
Catalent to buy Bristol-Myers plant to grow biologics, European business
June 19, 2019 -
Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
June 19, 2019 -
Celgene dips out of deals ahead of mega-merger
June 17, 2019 -
Despite late-stage win, investors not sold on Global Blood sickle cell drug
June 14, 2019 -
Moody's: Amgen, Biogen, Gilead have 'high capacity' to do M&A
June 13, 2019 -
Sobi restructuring business around late-stage hematology, immunology drugs
June 12, 2019 -
NASH trial miss halves CymaBay's market value
June 11, 2019 -
NASH drugmaker stocks rebound after dip on FDA guidance
June 10, 2019 -
Sanofi finds new CEO in Novartis pharma head, Brandicourt to retire
June 7, 2019 -
Fresh off being bought, Apceth preps to supply Bluebird's gene therapy
June 6, 2019 -
Biotechs dive deeper into targeted cancer research, despite costs
June 5, 2019